Abstract
This retrospective case series evaluates the outcome of 21 dogs with grade II stage 2 mast cell tumour (MCT) treated with adequate local therapy and adjuvant systemic chemotherapy (prednisone, vinblastine and CCNU). The median survival for all dogs was 1359days (range, 188-2340). Median disease-free interval was 2120days (149-2325days). Dogs treated with surgery and chemotherapy had shorter survival (median, 1103days; 188-2010days) than those that underwent surgery, radiation therapy and chemotherapy as part of their treatment (median, 2056days; 300-2340days). Two patients had local recurrence in the radiation field and four patients had de novo MCT. Distant metastasis was not observed in any dogs. The results of this study suggest that, in the presence of loco-regional lymph node metastasis in grade II MCT, the use of prednisone, vinblastine and CCNU after adequate local-regional therapy can provide a median survival in excess of 40months.
| Original language | English (US) |
|---|---|
| Journal | Veterinary and Comparative Oncology |
| DOIs | |
| State | Accepted/In press - 2013 |
Fingerprint
Keywords
- Canine
- Chemotherapy
- Mast cell tumour
- Radiation therapy
- Surgery
ASJC Scopus subject areas
- veterinary(all)
Cite this
Aggressive local therapy combined with systemic chemotherapy provides long-term control in grade II stage 2 canine mast cell tumour : 21 cases (1999-2012)*. / Lejeune, A.; Skorupski, Katherine A; Frazier, S.; Vanhaezebrouck, I.; Rebhun, Robert B; Reilly, C. M.; Rodriguez, C. O.
In: Veterinary and Comparative Oncology, 2013.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Aggressive local therapy combined with systemic chemotherapy provides long-term control in grade II stage 2 canine mast cell tumour
T2 - 21 cases (1999-2012)*
AU - Lejeune, A.
AU - Skorupski, Katherine A
AU - Frazier, S.
AU - Vanhaezebrouck, I.
AU - Rebhun, Robert B
AU - Reilly, C. M.
AU - Rodriguez, C. O.
PY - 2013
Y1 - 2013
N2 - This retrospective case series evaluates the outcome of 21 dogs with grade II stage 2 mast cell tumour (MCT) treated with adequate local therapy and adjuvant systemic chemotherapy (prednisone, vinblastine and CCNU). The median survival for all dogs was 1359days (range, 188-2340). Median disease-free interval was 2120days (149-2325days). Dogs treated with surgery and chemotherapy had shorter survival (median, 1103days; 188-2010days) than those that underwent surgery, radiation therapy and chemotherapy as part of their treatment (median, 2056days; 300-2340days). Two patients had local recurrence in the radiation field and four patients had de novo MCT. Distant metastasis was not observed in any dogs. The results of this study suggest that, in the presence of loco-regional lymph node metastasis in grade II MCT, the use of prednisone, vinblastine and CCNU after adequate local-regional therapy can provide a median survival in excess of 40months.
AB - This retrospective case series evaluates the outcome of 21 dogs with grade II stage 2 mast cell tumour (MCT) treated with adequate local therapy and adjuvant systemic chemotherapy (prednisone, vinblastine and CCNU). The median survival for all dogs was 1359days (range, 188-2340). Median disease-free interval was 2120days (149-2325days). Dogs treated with surgery and chemotherapy had shorter survival (median, 1103days; 188-2010days) than those that underwent surgery, radiation therapy and chemotherapy as part of their treatment (median, 2056days; 300-2340days). Two patients had local recurrence in the radiation field and four patients had de novo MCT. Distant metastasis was not observed in any dogs. The results of this study suggest that, in the presence of loco-regional lymph node metastasis in grade II MCT, the use of prednisone, vinblastine and CCNU after adequate local-regional therapy can provide a median survival in excess of 40months.
KW - Canine
KW - Chemotherapy
KW - Mast cell tumour
KW - Radiation therapy
KW - Surgery
UR - http://www.scopus.com/inward/record.url?scp=84878310240&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84878310240&partnerID=8YFLogxK
U2 - 10.1111/vco.12042
DO - 10.1111/vco.12042
M3 - Article
C2 - 23721492
AN - SCOPUS:84939653326
JO - Veterinary and Comparative Oncology
JF - Veterinary and Comparative Oncology
SN - 1476-5829
ER -